Page last updated: 2024-10-25

deferiprone and Hemangioendothelioma

deferiprone has been researched along with Hemangioendothelioma in 1 studies

Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.

Hemangioendothelioma: A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dessì, C1
Leoni, G1
Moi, P1
Danjou, F1
Follesa, I1
Foschini, ML1
Morittu, M1
Zappu, A1
Defraia, E1
Bina, P1
Cunico, A1
Civolani, A1
Podda, RA1
Origa, R1

Other Studies

1 other study available for deferiprone and Hemangioendothelioma

ArticleYear
Thalassemia major between liver and heart: Where we are now.
    Blood cells, molecules & diseases, 2015, Volume: 55, Issue:1

    Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxam

2015